1015 Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

1015 Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.48K	Hold	7	–	–	﹤0.01%	274
2026 Q1	$3.13K	Buy	7 +1	+17%	+$466	﹤0.01%	274
2025 Q4	$2.72K	Buy	+6	New	+$2.59K	﹤0.01%	284

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

1015 Capital Partners's VRTX Position: Q2 2026 in Review

1015 Capital Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 7 shares worth $3.48K. The position accounts for ﹤0.01% of the portfolio, ranked #274.

1015 Capital Partners first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,742 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

1015 Capital Partners held 7 shares of Vertex Pharmaceuticals worth $3.48K as of Q2 2026.
1015 Capital Partners left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of 1015 Capital Partners's portfolio in Q2 2026, its #274 holding.
1015 Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
1,742 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on 1015 Capital Partners's 13F filing for Q2 2026, filed 21 Jul 2026.